Download Files:

Rp-8-CPT-cAMPS (sodium)

Products Details

Product Description

– Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI[1][2].

Web ID

– HY-120994

Shipping

– Room temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C16H14ClN5NaO5PS2

References

– [1]Dostmann WR , et, al. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3′,5′-cyclic phosphorothioates. J Biol Chem. 1990 Jun 25;265(18):10484-91.|[2]Roscioni SS, et, al. PKA and Epac cooperate to augment bradykinin-induced interleukin-8 release from human airway smooth muscle cells. Respir Res. 2009 Sep 29;10(1):88.|[3]Chaisakul J, et, al. In vivo and in vitro cardiovascular effects of Papuan taipan (Oxyuranus scutellatus) venom: Exploring “sudden collapse”. Toxicol Lett. 2012 Sep 3;213(2):243-8.

CAS Number

– 221905-35-7

Molecular Weight

– 509.86

SMILES

– O[C@H]1[C@](O[C@@](CO2)([H])[C@@]1([H])O[P@@]2([S-])=O)([H])N3C4=NC=NC(N)=C4N=C3SC(C=C5)=CC=C5Cl.[Na+]

Clinical Information

– No Development Reported

Research Area

– Inflammation/Immunology; Neurological Disease

Solubility

– 10 mM in DMSO

Target

– PKA

Pathway

– Stem Cell/Wnt

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.